Yan Chen

age ~56

from Holliston, MA

Get Report

Also known as:

Ya N Chen
Yan Chan
Chen Yan

Connected to:

Yan Chen Phones & Addresses

Holliston, MA
Framingham, MA
Natick, MA
Atlantic City, NJ
51-11 97Th St, Corona, NY 11368
Mays Landing, NJ

Resumes

Yan Chen Diamond Bar, CA

view source

Work:

Telegent Systems

Nov 2010 to 2000
Senior Product Marketing Manager Broadcom Corporation
Irvine, CA
Aug 2008 to Nov 2010
Product Line Manager Broadcom Corporation
Irvine, CA
Jun 2005 to Aug 2008
Product Marketing Manager Agilent Technologies
Singapore
Sep 2002 to Jul 2004
Senior Engineer Pixelmetrix Corporation
Singapore
Jul 1999 to Dec 2001
Design Engineer

Education:

Massachusetts Institute of Technology
Cambridge, MA
Jun 2005
Master of Engineering in Logistics Engineering National University of Singapore
Singapore
Jan 2001 to Jan 2003
MBA in Master of Business and Administration National University of Singapore
Singapore
Jan 1995 to Jan 1999
Bachelor in Electrical Engineering

Skills:

Mandarin

Yan Chen Malden, MA

view source

Work:

Edison Mission Energy

Feb 2011 to 2000
Quantitative Risk Analyst Georgia Institute of Technology
Atlanta, GA
Aug 2010 to Dec 2010
Graduate Teaching Assistant of Finance and Investments Edison Mission Marketing & TradingBoston, MA
May 2010 to Aug 2010 Wuhan University
Wuhan, CN
Jul 2007 to Jun 2009
Research Assistant at Financial Engineering Lab China Minsheng Banking Corporation
Xiamen, CN
Oct 2008 to Dec 2008
Credit Analyst Intern

Education:

Georgia Institute of Technology
Atlanta, GA
Aug 2009 to Dec 2010
Master of Science in Quantitative and Computational Finance Wuhan University
Wuhan, CN
Sep 2005 to Jun 2009

Lawyers & Attorneys

Yan Chen

Yan Chen - Lawyer

view source

Specialties:

Administrative Law
Criminal Law
Government Relations & Advisory
Regulatory Law
Litigation
Professional Responsibility

ISLN:

1000234976

Admitted:

2011

License Records

Yan Chen

Address:

Natick, MA 01760

License #:

25896 - Active

Issued Date:

Sep 18, 2008

Expiration Date:

Jun 30, 2018

Type:

Certified Public Accountant

Us Patents

Genes, Compositions, Kits And Methods For Identification, Assessment, Prevention, And Therapy Of Cervical Cancer
view source
US Patent:

7125663, Oct 24, 2006
Filed:

Jun 12, 2002
Appl. No.:

10/171311
Inventors:

Robert Schlegel - Auburndale MA, US
Yan Chen - Cambridge MA, US
Xumei Zhao - Burlington MA, US
John E. Monahan - Walpole MA, US
Shubhangi Kamatkar - Newton MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersh - Arlington MA, US
Assignee:

Millenium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C12Q 1/68
US Classification:

435 6, 435 723, 530350, 5303877, 5303913, 536 235, 536 2431, 436 65
Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.

Enforcement Of Security Policies For Kernel Module Loading
view source
US Patent:

7644271, Jan 5, 2010
Filed:

Nov 7, 2005
Appl. No.:

11/268232
Inventors:

Mikhail Cherepov - Lexington MA, US
Yan Chen - Boonton Township NJ, US
Assignee:

Cisco Technology, Inc. - San Jose CA
International Classification:

H04L 29/06
G06F 12/14
G06F 12/16
US Classification:

713164, 726 22, 726 23, 726 24
Abstract:

A method and computer program product for providing enforcement of security policies for kernel module loading is presented. File paths for shared library executable files opened by user processes are cached. When a request to load a kernel loadable module (KLM) is received, a previously cached file path for said KLM is retrieved, said file path mapping a location of an executable file from which said KLM was produced. A security policy is applied to said file path, wherein when said file path triggers a security policy rule then an action associated with a triggered rule is taken, and wherein when said file path does not trigger a security policy rule then said KLM request is allowed to proceed.

Genes, Compositions, Kits, And Methods For Identification, Assessment, Prevention And Therapy Of Cervical Cancer
view source
US Patent:

7846737, Dec 7, 2010
Filed:

Aug 25, 2006
Appl. No.:

11/510530
Inventors:

Robert Schlegel - Auburndale MA, US
Yan Chen - Acton MA, US
Xumei Zhao - Wayland MA, US
John E. Monahan - Walpole MA, US
Shubhangi Kamatkar - Newton MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

G01N 33/48
G01N 33/574
US Classification:

436 64, 435 6, 435 71, 435 723, 530350, 5303877, 536 235, 536 243
Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.

Pharmacokinetic Modulation And Compositions For Modified Fn3 Polypeptides
view source
US Patent:

7847062, Dec 7, 2010
Filed:

Jul 7, 2006
Appl. No.:

11/482641
Inventors:

Yan Chen - Lexington MA, US
Elena Getmanova - Lexington MA, US
Martin C. Wright - Boston MA, US
Alan S. Harris - Andover MA, US
Ai Ching Lim - Mercer Island WA, US
Jochem Gokemeijer - Boston MA, US
Lin Sun - West Roxbury MA, US
Michael Wittekind - Bainbridge Island WA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07K 14/78
A61K 38/39
US Classification:

530320, 530345, 530350, 530402, 514 12
Abstract:

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Inhibitors Of Type 2 Vascular Endothelial Growth Factor Receptors
view source
US Patent:

7858739, Dec 28, 2010
Filed:

Jun 5, 2006
Appl. No.:

11/448171
Inventors:

Yan Chen - Lexington MA, US
Elena Getmanova - Lexington MA, US
Martin C. Wright - Boston MA, US
Alan S. Harris - Andover MA, US
Ai Ching Lim - Newton MA, US
Jochem Gokemeijer - Arlington MA, US
Lin Sun - West Roxbury MA, US
Michael Wittekind - Bainbridge Island WA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07K 14/78
A61K 38/39
US Classification:

530324, 530345, 530350, 530402, 514 12
Abstract:

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Interleukin-13 Binding Proteins
view source
US Patent:

7915388, Mar 29, 2011
Filed:

Sep 7, 2007
Appl. No.:

11/899819
Inventors:

Chengbin Wu - Shrewsbury MA, US
Richard W. Dixon - Jefferson MA, US
Jonathan P. Belk - Sterling MA, US
Maria A. Argiriadi - Wayland MA, US
Hua Ying - Holden MA, US
Carolyn A. Cuff - Grafton MA, US
Terry L. Melim - Derry NH, US
Shankar Kumar - Pleasanton CA, US
Paul R. Hinton - Sunnyvale CA, US
Yan Chen - Fremont CA, US
Assignee:

Abbott Laboratories - Abbott Park IL
International Classification:

C12P 21/08
US Classification:

5303879, 4241331
Abstract:

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e. g. , in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Genes, Compositions, Kits, And Methods For Identification, Assessment, Prevention And Therapy Of Cervical Cancer
view source
US Patent:

8062892, Nov 22, 2011
Filed:

Jun 14, 2010
Appl. No.:

12/814849
Inventors:

Robert Schlegel - Auburndale MA, US
Yan Chen - Acton MA, US
Xumei Zhao - Wayland MA, US
John E. Monahan - Walpole MA, US
Shubhangi Kamatkar - Newton MA, US
Manjula Gannavarapu - Acton MA, US
Karen Glatt - Natick MA, US
Sebastian Hoersch - Arlington MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

G01N 33/48
G01N 33/574
US Classification:

436 64, 435 6, 435 71, 435 723, 530350, 5303877, 536 235, 536 243
Abstract:

The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.

Nucleic Acid Encoding 10Fn3 Polypeptide Inhibitors Of Type 2 Vascular Endothelial Growth Factor Receptors
view source
US Patent:

8324362, Dec 4, 2012
Filed:

May 26, 2010
Appl. No.:

12/788240
Inventors:

Yan Chen - Lexington MA, US
Elena Getmanova - Lexington MA, US
Martin C. Wright - Boston MA, US
Alan S. Harris - Andover MA, US
Ai Ching Lim - Newton MA, US
Jochem Gokemeijer - Arlington MA, US
Lin Sun - West Roxbury MA, US
Michael Wittekind - Bainbridge Island WA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07H 21/04
C12N 15/63
C12N 15/09
C12N 1/21
C12N 1/15
C12N 5/10
A61K 38/39
C07K 14/78
A61P 35/00
US Classification:

536 235, 435 691, 4352523, 4352542, 4353201, 435348, 435354, 435358, 435364, 435365, 514 93, 514 133, 530324
Abstract:

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.